Discussions

Currently, various platforms have been established to generate and analyzeiPSC-derived immune cells to promote the development of novel stem cell therapy. We can provide the following custom services based on different immune cells:

Scientists at Creative Biolabs have used almost all available approaches for the delivery of reprogramming factors. RNA reprogramming can be achieved through the transfection/transduction of synthetic mRNAs, microRNAs (miRNAs), RNA viruses, or synthetic RNA replicons. Direct delivery of reprogramming RNA (synthetic modified mRNA) can avoid integration of the transgene sequences. To facilitate the transition of iPS cells to clinical practice, a variety of technologies have been developed for transgene-free pluripotency reprogramming at Creative Biolabs, including reprogramming factor delivery by mRNA.

iPSCs (induced pluripotent stem cells) that can differentiate into any cell type have emerged as an effective platform for the construction of disease models. iPSC-based disease models have been used for studying the pathological mechanisms of disease and discovering novel therapies. Compared to animal models and immortalized cell systems, iPSC-based disease models offer patient-specific, scalable biologic material of various tissue types and a complicated genetic signature of human tissue.

Complement Factor B is part of the alternative pathway of the complement system. It can be cleaved by complement factor D yielding the noncatalytic chain Ba (~33 kD) and the catalytic subunit Bb (~60 kD). Creative Biolabs is an innovative and ambitious company that delivers value-added services. We own a brilliant antibody engineering platform, a protease inhibitor platform, and a drug discovery platform. We are fully equipped to partner with our clients who are doing or may have the desire to work on complement systems for drug discovery and validation.

The production of hybridomas is a way to develop mAbs for various targets used for research, diagnosis, or therapeutic purposes. In the production of the monoclonal antibody, hybridoma screening is a key step, which requires the rapid identification of positive clones from hundreds to thousands of hybridoma cell lines against the desired target. Here, Creative Biolabs has established a time-saving and labor-saving Hybridoma platform to quickly and effectively provide global clients with convenient and high-quality hapten-specific hybridoma screening services.

Commonly, positive antibody-secreting subclones are screened and selected by a solid-phase enzyme-linked immunosorbent assay (ELISA). As a specialist in customized antibody development, Creative Biolabs offers a broad range of hybridoma screening services for the production of mAbs to promote basic scientific research and clinical applications.

Designing a suitable hapten is a critical step in the whole process of producing a class- or compound-specific antibody. In terms of our extensive experience in hapten design, Creative Biolabs is confident in designing optimal hapten formats with high quality for your projects.

Creative Biolabs now offers a full spectrum of small-molecule antibody development services. To develop a specific antibody, we offer our clients class-specific or compound-classic haptens that have a suitable spacer length and/or spacer positions to best fit their projects.